Phio Pharmaceuticals Corp. (PHIO) - Ekuitas Perusahaan

Phio Pharmaceuticals (PHIO) ensures drug stability through strict adherence to temperature controls during transport. The firm's environmental footprint is minimal and limited to standard waste recycling. Unique patents for RNA delivery and rigorous FDA oversight guarantee business protection, while the metric stands at 0.01. This market price chart below illustrates the price action of the company, which develops innovative genetic medicines.

For RNA therapy developer Phio Pharmaceuticals (PHIO), which lacks a stable income stream, book capitalization serves as the measure of residual capital after all liabilities are settled. By analyzing the firm's book capitalization history, an investor assesses the R&D platform's ability to sustain operations through net assets, which is critical given the negative leverage and the absence of scalable margins during the clinical trial phase.